Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Fig. 2

Mean change from baseline in DAS28 (CRP) in response to abatacept administered in combination with one csDMARD. (a) Pooled for all non-MTX csDMARDs in individual interventional studies. (b) Data from the observational ACTION study (DAS28 (ESR, otherwise CRP)). (c) Pooled analysis from the ATTAIN and ARRIVE studies. Error bars show 95% CI. ABA abatacept, AZA azathioprine, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28 28-joint Disease Activity Score, ESR erythrocyte sedimentation rate, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, SSZ sulfasalazine

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us